Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States (US) Medical Centers

BACKGROUND: Dalbavancin (DALBA) was approved by the US Food and Drug Administration (2014) and European Medicines Agency (2015) for treating acute bacterial skin and skin structure infections. Dalbavancin activity was assessed against a large collection of S. aureus clinical isolates with decreased...

Descripción completa

Detalles Bibliográficos
Autores principales: Sader, Helio S, Mendes, Rodrigo E, Duncan, Leonard R, Pfaller, Michael A, Flamm, Robert K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631506/
http://dx.doi.org/10.1093/ofid/ofx163.934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631506/
http://dx.doi.org/10.1093/ofid/ofx163.934

Ejemplares similares